|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,700.00 GBX | -0.35% |
|
+1.11% | -0.54% |
| 05-12 | AstraZeneca's Phase 3 Trial Shows Significant Results in Patients With Hypoparathyroidism | MT |
| 05-12 | AstraZeneca hails phase-3 trial results for hypoparathyroidism drug | AN |
| Capitalization | 288B 246B 225B 213B 395B 27,564B 399B 2,683B 1,045B 13,074B 1,081B 1,058B 45,428B | P/E ratio 2026 * |
23.4x | P/E ratio 2027 * | 20.6x |
|---|---|---|---|---|---|
| Enterprise value | 307B 262B 240B 227B 422B 29,404B 426B 2,862B 1,115B 13,947B 1,153B 1,128B 48,461B | EV / Sales 2026 * |
4.85x | EV / Sales 2027 * | 4.46x |
| Free-Float |
96.63% | Yield 2026 * |
1.8% | Yield 2027 * | 1.9% |
Last Transcript: AstraZeneca PLC
Trading AstraZeneca PLC
| 1 day | -0.22% | ||
| 1 week | +1.14% | ||
| Current month | -1.63% | ||
| 1 month | -8.46% | ||
| 3 months | -9.25% | ||
| 6 months | +1.67% | ||
| Current year | -0.51% |
| 1 week | 13,188 |  | 13,814 |
| 1 month | 12,356 | | 15,122 |
| Current year | 12,356 | | 15,732 |
| 1 year | 9,932 | | 15,732 |
| 3 years | 9,461 | | 15,732 |
| 5 years | 7,824 | | 15,732 |
| 10 years | 3,680 | | 15,732 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 66 | 30/09/2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 52 | 31/07/2021 |
Jeffrey Pott
CMP | Compliance Officer | - | 31/12/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 05/04/1999 | |
Pascal Soriot
BRD | Director/Board Member | 66 | 30/09/2012 |
Philip Broadley
BRD | Director/Board Member | 65 | 26/04/2017 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +5.24% | 5.17% | 27 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.22% | +1.14% | +34.77% | +14.33% | 288B | |
| +2.37% | +0.10% | +31.01% | +127.85% | 883B | |
| +1.28% | -0.57% | +45.49% | +39.48% | 540B | |
| +2.51% | +0.85% | +9.36% | +41.26% | 367B | |
| +1.67% | -1.00% | +20.39% | +10.73% | 328B | |
| +0.57% | +1.00% | +29.63% | +26.28% | 283B | |
| +0.98% | -0.69% | +39.71% | -4.07% | 278B | |
| +2.44% | +3.72% | -30.71% | -47.69% | 206B | |
| +2.03% | +2.03% | +22.39% | +44.36% | 181B | |
| +1.06% | +1.09% | +29.97% | +72.62% | 168B | |
| Average | +1.28% | +1.07% | +23.20% | +32.52% | 352.13B | |
| Weighted average by Cap. | +1.33% | +0.63% | +26.76% | +49.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 63.32B 54.01B 49.53B 46.89B 86.89B 6,061B 87.72B 590B 230B 2,875B 238B 233B 9,989B | 67.11B 57.24B 52.49B 49.69B 92.09B 6,423B 92.96B 625B 243B 3,047B 252B 247B 10,586B |
| Net income | 12.46B 10.63B 9.75B 9.23B 17.1B 1,193B 17.26B 116B 45.2B 566B 46.75B 45.77B 1,965B | 14.1B 12.03B 11.03B 10.44B 19.35B 1,350B 19.53B 131B 51.15B 640B 52.91B 51.79B 2,224B |
| Net Debt | 19.23B 16.4B 15.04B 14.24B 26.38B 1,840B 26.63B 179B 69.76B 873B 72.15B 70.63B 3,033B | 11.57B 9.87B 9.05B 8.57B 15.88B 1,108B 16.03B 108B 41.99B 525B 43.43B 42.51B 1,826B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/05/26 | 13,718.00 p | -0.22% | 162,885 |
| 12/05/26 | 13,748.00 p | +1.82% | 3,257,867 |
| 11/05/26 | 13,502.00 p | +1.18% | 3,377,059 |
| 08/05/26 | 13,344.00 p | +0.23% | 2,521,880 |
| 07/05/26 | 13,314.00 p | -1.86% | 2,842,538 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition